Early testing solutions will be necessary to reduce the health burden of neurodegenerative disease. Once clinical symptoms manifest, substantial amounts of neurons have already been lost. For example, in Parkinson's disease, it is estimated that up to 60% of substantia nigra neurons are lost by the time motor symptoms appear.
Diagnostic reliance on clinical symptoms has impeded early enrollment in clinical trials, delayed the development of therapeutics aimed at slowing neurodegeneration, and hindered substantial breakthroughs in NGD treatment and management.
Current diagnostics for NGDs remain limited in breadth and accessibility. These limitations stem from the fact that clinical diagnoses come too late to mitigate neurodegeneration, assays quantifying protein buildup in the brain often fail to correlate with disease progression, and other diagnostic procedures are invasive (CSF tests require spinal taps) or constrained by geographical accessibility (imaging centers are often located in major cities).
Neurodegenerative diseases are characterized by neuron death. Early research shows that our tests can detect cell-specific biomarkers of neurodegeneration, potentially even years before clinical symptoms appear. Our neurodegenerative disease panels can give researchers objective biomarkers of the progression of neuron death in NGDs.
Our technology is designed to support patient care by offering:
